Bind Therapeutics Inc. (NASDAQ:BIND) Given Average Rating of “Hold” by Analysts
Bind Therapeutics Inc. (NASDAQ:BIND) has received an average recommendation of “Hold” from the six ratings firms that are currently covering the firm. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $6.00.
Several equities research analysts have commented on BIND shares. Stifel Nicolaus reissued a “hold” rating on shares of Bind Therapeutics in a report on Wednesday, July 6th. Zacks Investment Research downgraded Bind Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 11th.
Shares of Bind Therapeutics (NASDAQ:BIND) remained flat at $0.78 during midday trading on Friday. The firm has a 50 day moving average of $0.52 and a 200 day moving average of $1.17. Bind Therapeutics has a 12 month low of $0.35 and a 12 month high of $5.24.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/bind-therapeutics-inc-nasdaqbind-given-average-rating-of-hold-by-analysts.html
An institutional investor recently bought a new position in Bind Therapeutics stock. Jacobs Levy Equity Management Inc. purchased a new position in shares of Bind Therapeutics Inc. (NASDAQ:BIND) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 89,900 shares of the company’s stock, valued at approximately $198,000. Jacobs Levy Equity Management Inc. owned approximately 0.43% of Bind Therapeutics as of its most recent SEC filing.
Bind Therapeutics Company Profile
BIND Therapeutics, Inc is a biotechnology company. The Company is engaged in developing targeted therapeutics, primarily for the treatment of cancer. The Company’s product candidates are based on polymeric nanoparticles called ACCURINS, which are engineered to target specific cells and tissues in the body at sites of disease.
Receive News & Ratings for Bind Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bind Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.